Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Date:4/23/2008

immune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung and gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materia
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Animal Health ... About Animal Health Animal health refers ... or treat animals to enhance their quality of ... of animal food. The Global Animal Health market ...
(Date:8/27/2014)... 2014 Sihuan Pharmaceutical Holdings Group Ltd. ... leading pharmaceutical company with the largest cardio-cerebral vascular ... prescription drug market, today announced the unaudited ... (collectively the "Group") for the six months ended ... HighlightsFor the Six months ended 30 JuneKey Income ...
(Date:8/27/2014)... , Aug. 27, 2014 ... research report is available in its ... for Application and Approval of Imported ... Practices (2014 Edition) ... Now, Chinese regulations on medical ...
Breaking Medicine Technology:Global Animal Health Market 2014-2018 2Global Animal Health Market 2014-2018 3Global Animal Health Market 2014-2018 4Global Animal Health Market 2014-2018 5Global Animal Health Market 2014-2018 6Global Animal Health Market 2014-2018 7Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10
... 10 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), ... the treatment of cancer and,hepatitis C virus (HCV) ... protocol with the Drug Controller General of India ... efficacy trial of bavituximab in combination,with the chemotherapy ...
... Results in 2.7 log10 (>99%) Mean HCV RNA Decrease with No ... Serious Adverse Events - ... 8:30AM (ET) Today -, PRINCETON, N.J., Sept. 10 Pharmasset, Inc.,(Nasdaq: ... of monotherapy in 40 patients chronically,infected with hepatitis C virus (HCV) who have ...
Cached Medicine Technology:Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 4R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients 2R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients 3R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients 4R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients 5R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients 6
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 ... business sector recently launched a “Video” section located ... and general information on various cannabis companies in ... can find an assortment of news clips, interviews, ... and announcements. A portion of the videos can ...
(Date:8/28/2014)... The Foundation for Women’s Cancer will ... alerting women to the link between obesity and endometrial ... endometrial cancer. , Endometrial cancer is the most ... More than 52,600 will learn of a diagnosis this ... weight management challenges to know the early warning signs ...
(Date:8/28/2014)... veEDIS Clinical Systems, LLC has successfully ... in Lawrence Medical Center, located in Moulton, Alabama. ... patient care, veEDIS is a key ingredient in ... the authorized, confidential exchange of patient information at ... designed in accordance with clinical workflows and best ...
(Date:8/28/2014)... Baltimore, MD (PRWEB) August 28, 2014 ... has received Diamond level Allergan Privilege Program status ... widely used treatments as Botox, Juvederm, and Voluma. Maryland ... exemplary and prolific use of these treatments. The dermatologists ... in injectable treatments, and are one of the leading ...
(Date:8/28/2014)... It is not uncommon for people to sink into ... face ridicule and judgment and find it easier to just ... why they keep gaining weight and just cannot seem to ... eating more and gaining more, leaving them feeling distain toward ... helped thousands safely, successfully and rapidly improve their confidence ...
Breaking Medicine News(10 mins):Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:Foundation for Women's Cancer Alerts Women to Link Between Obesity and Endometrial Cancer 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 3Health News:Maryland Laser Skin and Vein Receives Diamond Status From Allergan 2Health News:Diet Doc’s Medical Weight Loss Programs Announce New Help for Patients Who Want to Overcome Depression Caused by Excess Weight 2Health News:Diet Doc’s Medical Weight Loss Programs Announce New Help for Patients Who Want to Overcome Depression Caused by Excess Weight 3
... electronic, and patients, caregivers, and healthcare providers are ... health information. Now three institutions are teaming up ... best access this information. The Children,s ... based in Philadelphia, are partnering with Boston public ...
... for hepatitis C patients with end-stage liver disease are nearly ... to a Henry Ford Hospital study. Although infection ... the specific impact of the disease,s progressive severity on health ... severity of hepatitis C-related liver disease increases with age, and ...
... Scientists at Rochester Institute of Technology and Dowling College are ... cards, they are matching the protein to the job it ... drugs that target proteins and switch on or off specific ... funded by a $417,000 grant from the National Institutes of ...
... destroyed in type 1 diabetes Type 1 ... of sugar (glucose) in the blood. It is caused ... cells in their pancreas that produce the hormone insulin, ... about the mechanisms regulating the sensitivity and resistance of ...
... HealthDay Reporter , SUNDAY, Nov. 6 (HealthDay News) ... evoke the holiday season for some. For others, those ... noses and sneezing to asthma attacks. Allergists say ... have complaints from their patients about reactions to them. ...
... become fathers for the first time, they show significant decreases ... 19-year study. Researchers assessed more than 200 at-risk boys ... how men,s crime, tobacco, alcohol, and marijuana use changed over ... man,s negative behavior, they had not isolated the additional effects ...
Cached Medicine News:Health News:Grant will help bridge digital divide for people with disabilities 2Health News:Grant will help bridge digital divide for people with disabilities 3Health News:The economic cost of advanced liver disease 2Health News:Opening the data bank -- scientists try to match new protein structures 2Health News:JCI online early table of contents: Nov. 7, 2011 2Health News:JCI online early table of contents: Nov. 7, 2011 3Health News:JCI online early table of contents: Nov. 7, 2011 4Health News:JCI online early table of contents: Nov. 7, 2011 5Health News:JCI online early table of contents: Nov. 7, 2011 6Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3Health News:Fatherhood can help change a man's bad habits 2
... benchtop coagulation analyzers feature Stago's ... detection. This method eliminates interference ... optically dense samples or reagents. ... preprogrammed assays with curve storage, ...
The CA-50 is a compact semi-automated coagulation analyzerproviding 4-parameter random access....
HemoSite meter can be used to measure the effects of transfusion or the treatment of deficiency states. It is fast, easy, convenient and discrete....
... II is a fully automated analyzer that ... hands-on time by the operator. The Variant ... specimen tubes. It reads the bar code, ... injects the specimen into the chromatographic station ...
Medicine Products: